JPMorgan Chase & Co. Has $164.82 Million Stock Position in STERIS plc $STE

JPMorgan Chase & Co. cut its holdings in shares of STERIS plc (NYSE:STE) by 1.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 666,103 shares of the medical equipment provider’s stock after selling 7,843 shares during the quarter. JPMorgan Chase & Co.’s holdings in STERIS were worth $164,821,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Steigerwald Gordon & Koch Inc. bought a new position in STERIS during the third quarter worth $25,000. Cloud Capital Management LLC acquired a new stake in STERIS in the 3rd quarter worth $29,000. Spurstone Advisory Services LLC bought a new position in STERIS during the second quarter valued at about $29,000. Geneos Wealth Management Inc. increased its stake in STERIS by 416.0% during the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 104 shares during the period. Finally, TruNorth Capital Management LLC acquired a new position in STERIS in the 3rd quarter valued at approximately $37,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Trading Down 0.3%

Shares of STE opened at $250.55 on Friday. The company has a current ratio of 2.48, a quick ratio of 1.75 and a debt-to-equity ratio of 0.26. The stock has a market cap of $24.57 billion, a PE ratio of 34.94 and a beta of 1.03. STERIS plc has a 1 year low of $204.90 and a 1 year high of $269.44. The stock has a 50 day simple moving average of $256.10 and a 200-day simple moving average of $251.27.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.During the same period in the previous year, the business earned $2.32 EPS. The firm’s revenue for the quarter was up 9.2% on a year-over-year basis. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, sell-side analysts predict that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Investors of record on Tuesday, February 17th will be given a dividend of $0.63 per share. The ex-dividend date is Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. STERIS’s dividend payout ratio (DPR) is 35.15%.

Wall Street Analyst Weigh In

STE has been the topic of a number of research reports. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Wall Street Zen lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $275.20.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.